Glp-1

Below both sides: the key questions, where they part ways and how each answer holds up

Mainstream views

Proven efficacy for diabetes and obesity

GLP-1 is an incretin hormone that boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. Receptor agonists such as liraglutide, semaglutide and tirzepatide (a dual GIP/GLP-1 agonist) lower blood glucose. In large trials they produce substantial weight loss, roughly 15% or more of body weight with the most potent agents. Next-generation drugs such as the triple agonist retatrutide are moving toward regulatory filing. Lilly is expected to apply for FDA approval in early 2027, and a large trial recently showed benefit for knee osteoarthritis symptoms (substack.com).

Benefits beyond weight and glucose

Major outcome trials show that semaglutide reduces major adverse cardiovascular events in people with obesity and established heart disease (SELECT). Benefits have also been reported for kidney disease (FLOW), heart failure with preserved ejection fraction and sleep apnea. Professional bodies increasingly treat obesity as a chronic, relapsing disease that warrants long-term pharmacotherapy. Observational data support this view. A large Italian study found that people with diabetes who stopped GLP-1 drugs had more major cardiovascular events than those who stayed on them.

Real but manageable risks, with access and cost challenges

Common side effects are gastrointestinal: nausea, vomiting, diarrhea and constipation. These usually ease with gradual dose escalation. Rarer risks include gallbladder disease, pancreatitis and possible muscle and bone loss with rapid weight loss. Regulators have also recently highlighted a small increased risk of an eye complication, about 2.6 extra cases per 100,000 person-years (substack.com). Weight regain after stopping is common, which supports long-term use. Cost, insurance coverage, supply and equitable access remain the main practical obstacles. Experts emphasize use alongside lifestyle intervention and clinical supervision.

Conclusion

The mainstream view is that GLP-1-based drugs are among the most important therapeutic advances in metabolic medicine in decades. They are effective for type 2 diabetes and obesity and show growing cardiovascular and renal benefits. Their risks are generally modest but need monitoring. The main open issues are long-term safety, durability after discontinuation, affordability and equitable access.

Alternative views

Lifestyle and food-system change, not lifelong drugs

Some physicians and nutrition advocates argue that GLP-1s treat a symptom of an industrial food environment. They point to ultra-processed food, marketing and sedentary work as the root causes. They say weight regain after stopping is evidence of dependence rather than cure. A large Italian study reported more cardiovascular events in diabetics who stopped the drugs (substack.com). Supporters say this strengthens the case for upstream prevention, such as food policy and low-carbohydrate or whole-food diets, and for not building a population-wide drug habit.

Attributed to: Associated with Robert Lustig (UCSF), Dr. David Ludwig (Harvard/Boston Children's), and the Physicians Committee for Responsible Medicine. I am not certain how each would phrase it.

Safety signals are under-appreciated

Critics say side effects are still emerging and may be underweighted. Examples include gastroparesis, pancreatitis, muscle and bone loss, and the optic nerve complication NAION, which now carries a new warning of about 2.6 extra cases per 100,000 patient-years (substack.com). They argue that mass use by healthy-ish people needs a higher safety bar than treatment of diabetes. Patients who developed gastroparesis have also sued the manufacturers.

Attributed to: Plaintiffs' lawyers in the multidistrict gastroparesis litigation against Novo Nordisk and Eli Lilly, and some ophthalmology researchers such as Joshua Ehrlich and colleagues at Harvard. Specific wording of their positions is my own synthesis.

Obesity-drug boom medicalizes bodies and fuels weight stigma

Fat-acceptance and Health at Every Size advocates argue that treating body size as a disease to be drugged reinforces anti-fat bias. They say weight is a poor proxy for health. They also worry about pressure on children and about eating-disorder risk. They argue the evidence base is mostly about weight and biomarkers, and that dieting-style outcomes, including regain, repeat an old pattern.

Attributed to: Health at Every Size proponents such as Lindo Bacon and Linda Bacon, and writers such as Aubrey Gordon. Their positions on the drugs specifically vary.

Access and pricing are the real problem, not the molecule

A policy-left view holds that GLP-1s work but are priced as a monopoly product. Costs are high, insurers and employers ration coverage, and compounded alternatives became a gray-market lifeline. Advocates call for price negotiation, generics once patents lapse abroad, and public-sector manufacturing. They say a drug that could cut diabetes, heart and possibly arthritis burdens, as the retatrutide knee trial suggests, is wasted if only the affluent can afford it.

Attributed to: Senator Bernie Sanders, who has pressed Novo Nordisk on pricing, and health-economics commentators such as those at KFF. I am unsure of individual current positions.

The key questions

Where they part ways, and how each answer holds up. An answer stands or falls on what it explains and how it survives criticism, not on who holds it.

Add a tint

A tint shows how one school of thought would answer these questions. The two views stay as they are.

  • Does regain after stopping show that obesity needs long-term drug treatment, or that the drugs create dependence without addressing causes?

    Mainstream: Regain shows obesity is a chronic, relapsing condition that, like hypertension, needs continued treatment.

    Alternative: Regain shows the drugs suppress a symptom while the food environment and diet remain the root cause, so prevention and diet change should come first.

    The mainstream answer holds up better, for now. The alternative cannot show lifestyle programmes with durable results comparable to the drugs, and its use of the regain evidence fits the mainstream reading equally well.

    How each answer holds up

    What it explains

    Mainstream: It accounts for regain after stopping, the cardiovascular events seen after discontinuation, and the similar pattern seen when other chronic-disease drugs are stopped.

    Alternative: It accounts for why obesity rates rose with ultra-processed food and why the drugs do not lead to lasting change on their own.

    What would prove it wrong

    Mainstream: If people who stayed on treatment did no better than those who stopped, or if weight and risk stayed down after stopping, the answer would fail. Trials show regain after stopping. The discontinuation outcome data are observational and open to confounding.

    Alternative: If diet-based programmes produced weight loss and cardiovascular benefit as large and durable as the drugs do, this would be supported. Such durable results at population scale have mostly not been observed.

    Weak spot

    Mainstream: The Italian discontinuation finding is observational. People who stop may differ in health, income or adherence, so it cannot show that stopping caused the extra events.

    Alternative: It cites the same discontinuation data as proof of dependence, but those data fit the chronic-disease reading equally well. It also does not explain why diet-based approaches have so rarely kept weight off.

  • Are the safety risks of GLP-1 drugs modest and manageable, or under-appreciated, especially for mass use by relatively healthy people?

    Mainstream: Risks are mostly gastrointestinal and manageable, with rare serious events such as the small NAION increase that monitoring can handle.

    Alternative: Side effects are still emerging and underweighted, and use by healthier people needs a higher safety bar.

    The mainstream answer holds up better, for now. The one confirmed signal is small in absolute terms, and the alternative gives no measured harm large enough to change the balance. The lack of long-term data in healthy users keeps the question partly open.

    How each answer holds up

    What it explains

    Mainstream: It accounts for the trial and real-world safety data and the favourable cardiovascular and kidney outcomes.

    Alternative: It accounts for the NAION warning, the gastroparesis claims and the fact that long-term data are limited.

    What would prove it wrong

    Mainstream: If large long-term surveillance showed serious harms, such as widespread gastroparesis or optic or pancreatic events, outweighing benefits in healthier users, the answer would fail. The NAION signal is small. Long-term data in low-risk users are still limited.

    Alternative: If rates of gastroparesis and other harms in large controlled data stay close to background levels, the answer would fail. The NAION warning is real but small in absolute terms. Gastroparesis causation is still disputed.

    Weak spot

    Mainstream: Long-term safety in low-risk people is called an open issue, so 'modest' rests partly on trials in higher-risk groups. Rare harms such as muscle and bone loss are less well measured.

    Alternative: Its main example, NAION, adds about 2.6 cases per 100,000 patient-years, which is small. Lawsuits show that claims were made, not that the drug caused the harm. The 'higher bar' has no stated threshold.

  • Is treating body size with drugs harmful medicalization that increases stigma, or appropriate treatment of a disease?

    Mainstream: Obesity is a chronic disease that warrants long-term drug treatment.

    Alternative: Treating size as a disease reinforces anti-fat bias, and weight is a poor proxy for health.

    A question of values. Mainstream weighs the measurable health gains from treating weight more heavily, while the alternative weighs the risks of stigma, eating disorders and defining bodies as diseased more heavily.

  • Should policy focus on price and access for the drugs, or on upstream food and prevention policy?

    Mainstream: Expand coverage and affordability while keeping the drugs alongside lifestyle support and clinical supervision.

    Alternative: Negotiate prices, allow generics and public manufacturing, and invest in food policy rather than a population-wide drug habit.

    Still open. Whether price negotiation and generics widen access without hurting supply, and whether food policy can measurably change obesity rates, has not yet been observed.

    How each answer holds up

    What it explains

    Mainstream: It accounts for the proven benefits that go unused when people cannot pay or are denied coverage.

    Alternative: It accounts for monopoly pricing, rationed coverage and the gray-market compounding that grew from scarcity.

    What would show it failing

    Mainstream: The policy fails if wider coverage leads to poor adherence or unaffordable budgets with no better outcomes. That could be corrected by adjusting criteria.

    Alternative: The policy fails if price cuts do not widen use, or if food policy does not move obesity rates. Food policy has had little measured effect so far.

    Weak spot

    Mainstream: It does not say how budgets can cover a very large eligible population at current prices.

    Alternative: The two alternative positions pull apart: the price camp wants more drug use, while the food camp wants less. The food-policy part has little evidence of effect at scale.

Where they agree

  • GLP-1 receptor agonists such as semaglutide and tirzepatide lower blood glucose and cause substantial weight loss in trials.
  • Weight is commonly regained after the drugs are stopped.
  • Gastrointestinal side effects are common, and NAION (an optic nerve complication) now carries a regulatory warning of about 2.6 extra cases per 100,000 patient-years.
  • Cost, insurance coverage and unequal access limit who actually gets these drugs.

Your verdict

Which side made the stronger case?
Did reading both sides change your mind?

Your badge

Read both sides to the end and earn a badge to share. Most people never open the other one.

  • Mainstream
  • Alternative

References

  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
  • Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 2023.
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  • Perkovic V et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). New England Journal of Medicine, 2024.
  • Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 2018.
  • Glucagon-like peptide-1 - Wikipedia
  • GLP-1 Drugs (GLP-1 Agonist) - List of Brands & Generics

Comments

No comments yet. Be the first to comment!